ZM 336372

• CAT Number: I002601
• CAS Number: 208260-29-1
• Molecular Formula: C₂₃H₂₃N₃O₃
• Molecular Weight: 389.45
• Purity: ≥95%
• Synonyms: 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide
• Target: Apoptosis
• Solubility: DMSO ≥78mg/mL; Water <1mg/mL; Ethanol ≥6mg/mL
• Storage: 3 years -20C powder
• IC50: 70 nM
• InChI: InChI=1S/C23H23N3O3/c1-15-7-10-18(24-23(29)17-5-4-6-19(13-17)26(2)3)14-21(15)25-22(28)16-8-11-20(27)12-9-16/h4-14,27H,1-3H3,(H,24,29)(H,25,28)
• InChIKey: PYEFPDQFAZNXLI-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)N(C)C)NC(=O)C3=CC=C(C=C3)O

ZM 336372 (Cat No.:I002601) is a compound that functions as a selective inhibitor of the RAF kinases, particularly RAF-1 and BRAF. RAF kinases are key components of the mitogen-activated protein kinase (MAPK) signaling pathway, which regulates cell growth and proliferation. By inhibiting RAF kinases, ZM 336372 disrupts the MAPK signaling pathway, which can impact the growth and survival of cancer cells with aberrant RAF signaling, such as those with BRAF mutations. ZM 336372 has been investigated in preclinical and early clinical studies for its potential as an anti-cancer agent, particularly in melanoma and other malignancies where aberrant RAF signaling is implicated.

Reference

[1]. Hall-Jackson CA, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol, 1999, 6(8), 559-568.
[2]. Wartenberg M, et al. Reactive oxygen species-mediated regulation of eNOS and iNOS expression in multicellular prostate tumor spheroids. Int J Cancer, 2003, 104(3), 274-282.
[3]. Van Gompel JJ, et al. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther, 2005, 4(6), 910-917.